Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

5 results
Display

Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma

Iijima M, Okonogi N, Nakajima N, Morokoshi , Kanda H, Yamada T, Kobayashi , Banno K, Wakatsuki , Yamada S, Kamada T, Aoki D, Hasegawa S

OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer

Kunitomi H, Kobayashi , Wu RC, Takeda T, Tominaga E, Banno K, Aoki D

OBJECTIVE: With the emerging significance of genetic profiles in the management of endometrial cancer, the identification of tumor-driving genes with prognostic value is a pressing need. The LAMC1 gene, encoding...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer

Kobayashi , Banno K, Kunitomi H, Tominaga E, Aoki D

Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women. Although standard chemotherapy is the established treatment for ovarian cancer, the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer

Takeda T, Tsuji K, Banno K, Yanokura M, Kobayashi , Tominaga E, Aoki D

OBJECTIVE: Lynch syndrome is a cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes. Lynch syndrome only causes about 0.4% of cases of ovarian cancer, which...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D

OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr